Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms

Leukemia

Volumn 23, Issue 9, 2009, Pages 1577-1586

  Wang, J ^a,b   Ishii, T ^a   Zhang, W ^a   Sozer, S ^a   Dai, Y ^a   Mascarenhas, J ^a   Najfeld, V ^a,c,d   Zhao, Z J ^b,e   Hoffman, R ^a,d   Wisch, N ^a   Xu, M ^a,d  

^a Tisch Cancer Institute   (United States)

^b JILIN UNIVERSITY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Myeloproliferative Disorder Research Consortium   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

JAK2V617F; Mast cell; MplW515L; Myeloproliferative neoplasms

Indexed keywords

CD34 ANTIGEN; ERLOTINIB; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ARTICLE; CELL CULTURE; GENETICS; HUMAN; MAST CELL; MUTATION; MYELOID METAPLASIA; PATHOLOGY; PHYSIOLOGY; POLYCYTHEMIA VERA; THROMBOCYTHEMIA;

ANTIGENS, CD34; CELLS, CULTURED; HUMANS; JANUS KINASE 2; MAST CELLS; MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; QUINAZOLINES; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, ESSENTIAL;

EID: 70349306855     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.85     Document Type: Article

References (55)

1. Hoffman R, Xu M, Finazzi G, Barbui T. The polycythemias. In: Hoffman R, Benz Jr E, Shattil S, Furie B, Silberstein L, McGlave P, Heslop H (eds). Hematology: Basic Principles and Practice, 5th edn. Churchill Livingstone: Philadelphia, 2008, 1073-1108.
2. Mesa RA. Clinical and scientific advances in the Philadelphiachromosome negative chronic myeloproliferative disorders. Int J Hematol 2002; 76: 193-203.
3. Panani AD. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications. Cancer Lett 2007; 255: 12-25. Review.
4. Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 2002; 119: 558-566.
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
7. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
8. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
9. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788-22792.
10. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
11. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
12. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274-4281.
13. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-1660.
14. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2V617F. PLoS ONE 2006; 1: e18.
15. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006; 66: 11156-11165.
16. Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008; 111: 5109-5117.
17. Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2V617F. Leukemia 2008; 22: 87-95.
18. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J et al. Ratio of mutant JAK2V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931-3940.
19. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295: 913-916.
20. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58: 916-919.
21. Raskind WH, Jacobson R, Murphy S, Adamson JW, Fialkow PJ. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. J Clin Invest 1985; 75: 1388-1390.
22. Tsukamoto N, Morita K, Maehara T, Okamoto K, Sakai H, Karasawa M et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol 1994; 86: 253-258.
23. Williams CK, Ogunmola GB, Abugo O, Ukaejiofo EO, Esan GJ. Polycythaemia rubra vera associated with unbalanced expression of the X chromosome and monoclonality of T lymphocytes. Acta Haematol 1983; 70: 229-235.
24. Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 1988; 2: 658-660.
25. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood 2003; 101: 1981-1983.
26. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30: 229-236.
27. Akin C. Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 2005; 114: 61-69.
28. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006; 108: 3128-3134.
29. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M et al. The JAK2V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006; 103: 6224-6229.
30. Delhommeau F, Dupont S, Tonetti C, Massé A, Godin I, Le Couedic JP et al. Evidence that the JAK2G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and diopathic myelofibrosis. Blood 2007; 109: 71-77.
31. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2V617F mutation involves B-and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007; 136: 745-751.
32. Hu WY, Zhao Y, Ishii T, Sozer S, Shi J, Zhang W et al. Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis. Br J Haematol 2007; 137: 378-379.
33. Chaligné R, James C, Tonetti C, Besancenot R, Le Couédic JP, Fava F et al. Evidence for MPLW515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 2007; 110: 3735-3743.
34. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
35. Xu M, Bruno E, Chao J, Ni H, Lindgren V, Nunez R et al. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 2005; 105: 1699-1705.
36. Toru H, Eguchi M, Matsumoto R, Yanagida M, Yata J, Nakahata T. Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 1998; 91: 187-195.
37. Saito H, Kato A, Matsumoto K, Okayama Y. Culture of human mast cells from peripheral blood progenitors. Nat Protoc 2006; 1: 2178-2183.
38. Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007; 282: 3428-3432.
39. Ishii T, Zhao Y, Shi J, Sozer S, Hoffman R, Xu M. T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation. Leukemia 2007; 21: 2433-2441.
40. Ghinassi B, Sanchez M, Martelli F, Amabile G, Vannucchi AM, Migliaccio G et al. The hypomorphic Gata1low mutation alters the proliferation/ differentiation potential of the common megakaryocytic-erythroid progenitor. Blood 2007; 109: 1460-1471.
41. Sutton BJ, Gould HJ. The human IgE network. Nature 1993; 366: 421-428. Review.
42. Gilfillan AM, Kado-Fong H, Wiggan GA, Hakimi J, Kent U, Kochan JP. Conservation of signal transduction mechanisms via the human Fc epsilon RI alpha after transfection into a rat mast cell line, RBL 2H3. J Immunol 1992; 149: 2445-2451.
43. Nishida K, Yamasaki S, Ito Y, Kabu K, Hattori K, Tezuka T et al. Fc{epsilon}RI-mediated mast cell degranulation requires calciumindependent microtubule-dependent translocation of granules to the plasma membrane. J Cell Biol 2005; 170: 115-126.
44. Furuno T, Teshima R, Kitani S, Sawada J, Nakanishi M. Surface expression of CD63 antigen (AD1 antigen) in P815 mastocytoma cells by transfected IgE receptors. Biochem Biophys Res Commun 1996; 219: 740-744.
45. D́az-Agust́n B, Escribano L, Bravo P, Herrero S, Nuñez R, Navalón R et al. The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. Br J Haematol 1999; 106: 400-405.
46. Escribano L, Orfao A, D́az Agust́n B, Cerveró C, Herrero S, Villarrubia J et al. Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. Cytometry 1998; 34: 223-228.
47. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108: 2435-2437.
48. Kitamura Y, Yokoyama M, Matsuda H, Ohno T, Mori KJ. Spleen colony-forming cell as common precursor for tissue mast cells and granulocytes. Nature 1981; 291: 159-160.
49. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978; 52: 447-452.
50. Kambe N, Hiramatsu H, Shimonaka M, Fujino H, Nishikomori R, Heike T et al. Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body. Blood 2004; 103: 860-867.
51. Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 2008; 283: 5258-5266.
52. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2007; 111: 5663-5671.
53. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ et al. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2V617F mutation. Clin Cancer Res 2008; 14: 788-796.
54. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13: 311-320.
55. Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F et al. LS104, a non-ATP-competitive smallmolecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 2008; 7: 1176-1184.